1. Home
  2. SPB vs DFTX Comparison

SPB vs DFTX Comparison

Compare SPB & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Spectrum Brands Holdings Inc.

SPB

Spectrum Brands Holdings Inc.

HOLD

Current Price

$83.72

Market Cap

1.8B

Sector

Miscellaneous

ML Signal

HOLD

DFTX

Definium Therapeutics Inc. Common Shares

N/A

Current Price

$24.62

Market Cap

1.7B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
SPB
DFTX
Founded
1906
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Sector
Miscellaneous
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.7B
IPO Year
1994
N/A

Fundamental Metrics

Financial Performance
Metric
SPB
DFTX
Price
$83.72
$24.62
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
8
Target Price
$82.40
$38.50
AVG Volume (30 Days)
326.4K
2.0M
Earning Date
05-07-2026
05-04-2026
Dividend Yield
2.31%
N/A
EPS Growth
N/A
N/A
EPS
2.16
N/A
Revenue
$3,802,100,000.00
N/A
Revenue This Year
$2.03
N/A
Revenue Next Year
$1.85
N/A
P/E Ratio
$38.81
N/A
Revenue Growth
20.86
N/A
52 Week Low
$49.99
$14.62
52 Week High
$86.96
$26.25

Technical Indicators

Market Signals
Indicator
SPB
DFTX
Relative Strength Index (RSI) 60.04 61.13
Support Level $72.94 $16.37
Resistance Level $86.23 $25.71
Average True Range (ATR) 2.35 1.48
MACD 0.59 0.06
Stochastic Oscillator 84.76 84.73

Price Performance

Historical Comparison
SPB
DFTX

About SPB Spectrum Brands Holdings Inc.

Spectrum Brands Holdings Inc is consumer products and home essentials company. The company is a supplier of consumer batteries, residential locksets, residential builders' hardware, grooming products and personal care products. The company manages the businesses in product-focused segments; Home and Personal Care, global Pet Care, and Home and Garden. The Company manufactures, markets and distributes its products globally in the North America, Europe, Middle East & Africa, Latin America, and Asia-Pacific.

About DFTX Definium Therapeutics Inc. Common Shares

Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a best-in-class care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).

Share on Social Networks: